QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.

Published

Journal Article

INTRODUCTION: A phase 2 study of eculizumab for treating myasthenia gravis (MG) used the quantitative myasthenia gravis score (QMG) and myasthenia gravis activities of daily living profile (MG-ADL) to evaluate baseline disease severity and treatment response. Correlations were then analyzed between these assessments. METHODS: Patients were given eculizumab or placebo during the first 16-week treatment period of the crossover study, with treatment assignments reversed for the second treatment period following a 5-week washout. QMG and MG-ADL scores at baseline and endpoint of each treatment period generated correlation coefficients for baseline status and treatment response during eculizumab therapy. RESULTS: Correlation strength between QMG and MG-ADL scores was higher for treatment response (R = 0.726; 95% confidence interval, 0.264-0.907; P = 0.0036) than for assessing baseline disease status (R = 0.552; 95% confidence interval, -0.022-0.839; P = 0.0495). CONCLUSIONS: MG-ADL may be more sensitive for assessing treatment response than point-in-time disease status. Muscle Nerve 56: 328-330, 2017.

Full Text

Duke Authors

Cited Authors

  • Howard, JF; Freimer, M; O'Brien, F; Wang, JJ; Collins, SR; Kissel, JT; MG (Phase2) Study Group,

Published Date

  • August 2017

Published In

Volume / Issue

  • 56 / 2

Start / End Page

  • 328 - 330

PubMed ID

  • 28010051

Pubmed Central ID

  • 28010051

Electronic International Standard Serial Number (EISSN)

  • 1097-4598

Digital Object Identifier (DOI)

  • 10.1002/mus.25529

Language

  • eng

Conference Location

  • United States